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Abstract
Background: Cardiovascular disease (CVD) mortality is substantially higher in Russia than in neighbouring Norway.
We aimed to compare blood pressure- and lipid-lowering medication use and proportion meeting treatment
targets between general population samples in the two countries in those with CVD and diabetes.
Methods: The study population was adults aged 40–69 years reporting a diagnosis of myocardial infarction (MI),
stroke and/or diabetes participating in cross-sectional population-based studies in Russia (Know Your Heart (KYH)
2015–18 N = 626) and Norway (The Tromsø Study 2015–16 (Tromsø 7) N = 1353). Reported medications were coded
according to the 2016 WHO Anatomical Therapeutic Chemical Classification system. Treatment targets were defined
using the Joint European Societies guidelines for CVD prevention in clinical practice (2016).
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Results: Age- and sex-standardized prevalence of use of lipid-lowering medications was higher in Tromsø 7 for all
three conditions with a disproportionately large difference in those reporting MI (+ 48% (95% CI 39, 57%)).
Proportion meeting treatment targets for LDL cholesterol was poor in both studies (age- and sex-standardized
prevalence of control KYH vs Tromsø 7: MI 5.1% vs 10.1%; stroke 11.6% vs 5.8%; diabetes 24.9% vs 23.3%). Use of
antihypertensive medication was higher in KYH for stroke (+ 40% (95% CI 30, 50%)) and diabetes (+ 27% (95% CI 19,
34%)) groups but approximately equal for the MI group (− 1% (95% CI -1, 1%)). Proportion meeting blood pressure
targets was lower in KYH vs Tromsø 7 (MI 51.8% vs 76.3%; stroke 49.5% vs 69.6%; diabetes 51.9% vs 63.9%).
Conclusions: We identified different patterns of medication use in people with CVD and diabetes. However despite
higher use of lipid-lowering medication in the Norwegian study treatment to target for total cholesterol was poor
in both Russian and Norwegian studies. In contrast we found higher levels of use of antihypertensive medications
in the Russian study but also that less participants met treatment targets for blood pressure. Further work should
investigate what factors are responsible for this seeming paradox and how management of modifiable risk factors
for secondary prevention could be improved.
Keywords: Secondary prevention, Russian Federation, Norway, Myocardial infarction, Stroke, Diabetes
Background
Cardiovascular disease (CVD) mortality is particularly
high in Russia, [1, 2] exceeding that in neighbouring
Norway by a factor of four in 2015 [3]. Excess mortality
in Russia contributes substantially to the CVD burden in
Europe as a whole.
Management of modifiable risk factors such as high
blood pressure and lipid levels following CVD diagnosis is
crucial for long term prognosis [4, 5]. This includes both
lifestyle changes and pharmacological management with
appropriate antihypertensive and lipid-lowering medica-
tions, and management of co-existing diabetes according
to regularly updated European treatment guidelines [5].
Management of blood pressure and lipid levels is also im-
portant in patients with diabetes to prevent CVD events.
EUROASPIRE IV [4] (2012–13) collected data from
clinical centres in 24 European countries including
Russia on management of CVD risk factors following
hospitalisation with coronary heart disease. It showed
that, although antihypertensive and lipid-lowering medi-
cations were widely used, control of these risk factors,
particularly lipids, was sub-optimal across Europe. The
three Russian centres achieved better control of blood
pressure among those taking antihypertensive medica-
tion than other European centres, but had lower use of
lipid-lowering medications and fewer patients reaching
targets for cholesterol reduction [6]. However, it is un-
likely that the Russian EUROASPIRE clinical centres, all
located within the Moscow oblast, are typical. The
EUROSPIRE findings with respect to blood pressure
control are inconsistent with data from Russian regis-
tries of CVD patients where levels of control were con-
siderably lower [7, 8]. Moreover a multi-centre
population survey found that the use of lipid-lowering
medication was substantially lower than found in EURO-
ASPIRE IV [9].
In the context of the extremely high levels of cardio-
vascular disease mortality in Russia we investigate here
whether there are differences in secondary prevention
(following myocardial infarction and stroke) and preven-
tion in a high risk group (those with diabetes) between
Russia and Norway, a neighbouring country with far
lower CVD mortality, using population-based samples to
capture real world practices.
Methods
The study population comprised individuals aged 40–69
years with a self-reported diagnosis of myocardial infarc-
tion (MI), stroke and/or diabetes and data on medication
use who were taking part in the Know Your Heart Study
[10] (KYH) conducted in two Russian cities (Arkhan-
gelsk and Novosibirsk (2015–18)) and the seventh wave
of the Tromsø Study (Tromsø 7) [11] conducted in the
Norwegian city of Tromsø (2015–16). These studies
were conducted in parallel as part of the Heart to Heart
project aimed at understanding the reasons for very high
rates of CVD mortality in Russia through comparisons
between the Know Your Heart Study and Tromsø 7
study. Several aspects of data collection between the
studies have been harmonized (including the ATC cod-
ing of medications, blood pressure measurement proto-
cols and calibration of lipid measurements) providing a
unique opportunity to compare the general population
of both countries.
Definition of disease status
As this paper focuses on secondary prevention, partici-
pants needed to be aware of their diagnosis (thereby ex-
cluding those with silent MIs or undiagnosed diabetes).
Therefore primary case definition was self-report of MI,
stroke and/or diabetes, defined using the questions
shown in Table 1.
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We tested more specific case definitions for diabetes,
restricting the sample to those who reported diabetes
and medication for diabetes (International WHO Ana-
tomical Therapeutic Chemical (ATC) codes: A10A,
A10B). Since this case-definition could exclude some eli-
gible individuals, such as those who control their dia-
betes with diet, this was only used in a sensitivity
analysis of robustness of findings.
A subset of participants in KYH who attended a med-
ical examination were also asked about diagnosis of MI
in a second interview including whether they were hos-
pitalised at the time of the event. Sensitivity analyses
with a sample restricted to those in KYH reporting dis-
ease in both questionnaires and hospitalisation for MI
were carried out to test the robustness of findings with a
more specific case definition.
Pharmacological management of blood pressure and
lipids
Both studies asked questions about use of antihyperten-
sive and lipid-lowering medication (see Table 1) but
there were differences in the procedures used.
In KYH, a baseline interview was administered by a
trained interviewer. Participants who reported ever being
diagnosed with hypertension were asked a series of ques-
tions about prescription and use of antihypertensive
medication (Table 1). An equivalent set of questions
were asked to those who reported ever having a diagno-
sis of high cholesterol. At the end of the interview all
participants were invited to attend a health check to
which they were asked to bring all their medications.
Trained interviewers asked about current medication
use and recorded the name, dose, indication and fre-
quency of use of medications (up to 7 medications).
In Tromsø 7, self-adminstered questionnares given to
all participants included questions about current or pre-
vious use of lipid-lowering and antihypertensives medi-
cations (Table 1). Next, participants were asked to state
the name of all (prescription and non-prescription) med-
icines they had used regularly during the last 4 weeks
(up to 20 medications). The questionnaire was checked
by a trained technician at the study site, and participants
had to confirm if no medication use was reported.
For both studies, listed medications were coded using
the International WHO Anatomical Therapeutic Chem-
ical (ATC) classification system version 2016 [12]. Antihy-
pertensive medication was defined as use of any
medications within the ATC classes C02, C03, C07, C08
or C09. Although this classification could include medica-
tions prescribed for other indications this was considered
appropriate given these medications have a therapeutic ef-
fect on blood pressure regardless of indication for treat-
ment. Lipid-lowering medication was defined as use of
any medications within the ATC class C10.
Given the focus here on comparing medication use be-
tween the studies, the main analyses are based on ATC
codes alone. Sensitivity analyses were conducted using a
broader definition of report of medication from ATC
codes as above and/or self-reported use of antihyperten-
sive or lipid-lowering medication (irrespective of
whether a relevant medication was identified among the
ATC codes) to investigate robustness of findings using a
broader definition of medication use.
Blood pressure and lipid levels
Blood pressure was measured using automatic blood
pressure monitors; OMRON 705 IT (OMRON Health-
care) in KYH, and Dinamap (ProCare 300, GE Health-
care) in Tromsø 7. In both studies three measurements
were taken separated by 2 min seated rest. In our ana-
lyses the mean of second and third readings were used.
Lipid levels were measured using serum blood sam-
ples. In KYH participants were instructed not to eat for
4 h prior to the examination. Collection procedures are
described in detail elsewhere [10]. LDL cholesterol
(LDL-C) was measured using the enzymatic color test
using AU 680 Chemistry System Beckman Coulter de-
vices at a central laboratory in Moscow. In Tromsø 7
participants were non-fasting. Blood samples collected in
SST tubes were left for 30 min at room temperature,
then centrifuged within 1 h for 10 min at 2000 g. Ana-
lyses were done within the same day at Department of
Laboratory Medicine at the University Hospital of North
Table 1 Questions on self-reported morbidity and use of antihypertensive and lipid-lowering medication
Know Your Heart (Russia) Tromsø 7 (Norway)
Self-reported
morbidity
Have you ever been told by a doctor (been diagnosed) that you have heart
attack/myocardial infarction
Do you have, or have you had a heart attack?
Have you ever been told by a doctor (been diagnosed) that you have stroke Do you have, or have you had a cerebral
stroke/brain haemorrhage?
Have you ever been told by a doctor (been diagnosed) that you have diabetes Do you have, or have you had diabetes?
Self-reported use of
medication
Do you take your prescribed blood pressure medication every day? (asked only
to participants reporting hypertension)
Do you use, or have you used blood pressure
lowering drugs?
Do you take your prescribed cholesterol medication every day? (asked only to
participants reporting high cholesterol)
Do you use, or have you used cholesterol
lowering drugs?
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Norway, Tromsø. LDL-C was measured using homoge-
neous enzymatic color method using Cobas 8000 Roche
devices. Given there were differences in laboratory
methods in terms of analytic methods and devices a cali-
bration study was performed comparing measurement of
LDL-C in both laboratories on a subset of the same sam-
ples. In accordance with the results, KYH LDL-C levels
were shifted by using the equation: LDL-C post calibra-
tion = − 0.66 + 1.11 (LDL-C pre-calibration).
Targets for control of blood pressure and lipids were
taken from the 2016 Joint European Societies guidelines
for CVD prevention in clinical practice [5].
The treatment target for blood pressure was defined as
< 140 mmHg systolic blood pressure (SBP) and < 90
mmHg diastolic blood pressure (DBP). Treatment guide-
lines for control of blood pressure in people with dia-
betes are markedly inconsistent between and within
countries. Here, in participants reporting diabetes and a
previous MI/stroke (at high risk of CVD), the more
stringent target of < 130 mmHg SBP and < 80 mmHg
DBP was used for blood pressure.
Meeting treatment targets for lipid levels was defined
as LDL-C < 1.8 mmol/L (very high risk) for participants
reporting MI, stroke, or diabetes with co-morbid MI/
stroke and < 2.6 mmol/L (high risk) for participants with
diabetes but no prior MI/stroke [5].
We also investigated prevalence of higher risk factor
levels of LDL-C ≥ 4.0 mmol/L, SBP ≥160 mmHg or DBP
≥100 mmHg.
Covariates
We adjusted for key socio-demographic indicators compar-
able between the two studies (age, sex and education). Edu-
cation was coded into three categories (lower, middle and
higher) based on the education system within each country.
In KYH these groups were lower (incomplete secondary
and vocational no secondary), middle (complete secondary,
vocational and secondary, specialised secondary) and higher
(incomplete higher, higher) education. For Tromsø 7, these
were lower (primary) middle (upper secondary) and higher
(university/university college) education.
As the standard of medical management of people
with prior MI, stroke or diabetes might explain differ-
ences between Norway and Russia we used a simple
proxy to investigate whether differences were explained
by differential health care use: whether participants had
visited a doctor in the past 12 months. In KYH, this was
any visit to a primary care (district) physician/polyclinic
cardiologist/other polyclinic specialist/hospital cardiolo-
gist or other hospital doctor. In Tromsø 7, this was any
visit to a general practitioner/hospital outpatient clinic
or medical specialist other than a general practitioner.
Visits to psychiatrists or psychologists were not included
given our focus on community CVD treatment.
Analysis
First in descriptive analyses we compared patterns of
medication use by study for each condition in terms of
1) prevalence of use of antihypertensive and lipid-
lowering medication and 2) prevalence of blood pressure
and lipids controlled to treatment guidelines. Preva-
lences were directly standardised by age and sex to the
European 2013 standard population. Then separate mul-
tivariable logistic regression models were fitted for each
outcome, with incremental adjustments for a) age and
sex b) education, and c) visiting a doctor in the past 12
months. The exposure in each model was study using
KYH as the reference group.
All analyses were conducted using Stata version 15 [13].
Results
The characteristics of the participants by condition and
study are shown in Table 2. The proportion of partici-
pants reporting at least two of the three conditions was
higher in KYH than in Tromsø 7. The proportion of par-
ticipants who visited a doctor in the past 12 months was
high in KYH (> 80% for all conditions) but even higher
in Tromsø 7 (> 90% for all conditions).
Use of lipid-lowering and antihypertensive medications
The age and sex-standardised prevalence of use of lipid-
lowering and antihypertensive medications by study are
shown in Figs. 1 and 2. Prevalences are shown for both
ATC codes and for self-reported use but with no specific
medication listed.
Using the ATC code definition, use of lipid-lowering
medications was higher in Tromsø 7 for all three condi-
tions but with an especially large difference in those
reporting MI. Use of medications differed markedly by
disease category in Tromsø 7, with much higher propor-
tion of those with MI using lipid-lowering medications
than those with stroke or diabetes. This striking difference
was not seen in KYH. When broadening the definition of
medication use to include those with self-reported use but
no ATC code the large between study differences among
participants with MI remained, but the differences for
stroke and diabetes narrowed. This was due to a higher
proportion of participants in KYH reporting use of lipid-
lowering medication but with no medication listed.
The prevalence of antihypertensive medication use
was similar in KYH and Tromsø 7 for those with MI,
but substantially higher in KYH than Tromsø 7 for those
with stroke and diabetes. These findings were robust to
the definition of medication use.
The between study differences in medication use
remained after adjustment for education and visiting a
doctor in the past 12 months but with some attenuation
of odds ratios for lipid-lowering medication after adjust-
ment for visiting a doctor (Tables 3 and 4).
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Between study differences in meeting treatment
guidelines for lipids and blood pressure
The proportion meeting treatment targets for lipid levels in
each study is shown in Table 3. The majority of participants
in each study had LDL-C levels which did not meet treat-
ment targets. Proportion meeting treatment targets for LDL-
C did not differ between the two studies in individuals with
any of the conditions either in the total population or among
those on medication. The exception to this was those with
stroke where among those on medication a higher propor-
tion met treatment targets in the KYH group, however it
should be noted this sub-group only included 43 participants.
Table 2 Characteristics of participants with myocardial infarction, stroke and diabetes in Know Your Heart (KYH) and Tromsø 7
Myocardial Infarction Stroke Diabetes
KYH Tromsø 7 KYH Tromsø 7 KYH Tromsø 7
N (%) N (%) N (%) N (%) N (%) N (%)
Total 240 (100) 376 (100) 144 (100) 309 (100) 341 (100) 792 (100)
Age 40–49 17 (7.1) 31 (8.2) 9 (6.3) 47 (15.2) 34 (10.0) 185 (23.4)
50–59 66 (27.5) 106 (28.2) 43 (29.9) 92 (29.8) 83 (24.3) 253 (31.9)
60–69 157 (65.4) 239 (63.6) 93 (63.9) 170 (55.0) 224 (65.7) 354 (44.7)
Sex Female 101 (42.1) 62 (16.5) 70 (48.6) 127 (41.1) 222 (65.1) 368 (46.5)
Male 139 (57.9) 314 (83.5) 74 (51.4) 182 (58.9) 119 (34.9) 424 (53.5)
Educational level Lower 27 (11.3) 114 (31.1) 15 (10.4) 82 (27.3) 28 (8.2) 220 (28.2)
Middle 143 (59.6) 121 (33.0) 85 (59.0) 102 (34.0) 205 (60.1) 248 (31.8)
Higher 70 (29.2) 132 (36.0) 44 (30.6) 116 (38.7) 108 (31.7) 312 (40.0)
Missing 0 9 0 9 0 12
Visited Doctor in
past 12 months
Yes 193 (80.4) 95.1 (95.1) 121 (84.0) 281 (91.8) 300 (88.0) 750 (95.4)
Missing 0 7 0 3 0 6
Smoking status Never 90 (37.8) 79 (21.4) 63 (43.8) 79 (26.2) 179 (52.5) 276 (35.6)
Ex-smoker 71 (29.8) 218 (58.9) 43 (29.9) 165 (54.6) 99 (29.0) 379 (48.8)
Current
smoker
77 (32.4) 73 (19.7) 38 (26.4) 58 (19.2) 63 (18.5) 121 (15.6)
Missing 2 6 0 7 0 16
Co-morbid MI Yes – – – – 39 (27.1) 31 (11.0) 40 (11.8) 61 (8.2)
Missing – – – – 0 26 1 47
Co-morbid stroke Yes 39 (16.3) 31 (8.8) – – – – 32 (9.4) 39 (5.3)
Missing 0 22 – – – – 0 50
Co-morbid
diabetes
Yes 40 (16.7) 61 (17.2) 32 (22.2) 39 (13.5) – – – –
Missing 0 21 0 21 – – – –
Any Co
morbiditya
Yes 67 (27.9) 85 (22.6) 59 (41.0) 63 (20.4) 60 (17.6) 93 (11.7)
Mean Blood
pressure (95% CI)c
SBP 136.6 (133.2, 139.9) 125.6 (122.5, 128.6) 136.7 (133.3, 140.1) 127.8 (125.5, 130.1) 137.0 (133.9, 140.1) 131.6 (130.4, 132.8)
DBP 85.2 (83.1, 87.3) 75.1 (73.4, 76.8) 84.3 (82.7, 85.8) 76.2 (74.8, 77.6) 85.0 (83.3, 86.8) 76.4 (75.8, 77.1)
Missing 1 1 3 2 2 3
Mean Cholesterol
Levels (95% CI)b,c
Total
cholesterol
5.3 (5.1, 5.4) 4.5 (4.3, 4.7)) 5.2 (5.0, 5.4) 5.0 (4.9, 5.2) 5.1 (4.9, 5.3) 5.1 (5.0, 5.2)
LDL-C 3.4 (3.3, 3.6) 2.8 (2.6, 3.0) 3.3 (3.1, 3.5) 3.2 (3.0, 3.3) 3.2 (3.1, 3.4) 3.3 (3.2, 3.3)
Missing 4 3 1 2 7 6
Mean HbA1c
(95% CI)b, c
6.0 (5.9, 6.2) 6.0 (5.9, 6.2) 6.1 (6.0, 6.3) 5.9 (5.7, 6.0) 7.4 (7.1, 7.6) 7.3 (7.2. 7.4)
Missing 5 8 3 5 7 14
Mean Body mass
index
(95% CI)c
30.2 (6.4) 29.1 (4.3) 29.6 (6.0) 27.7 (4.2) 32.8 (6.2) 30.2 (5.2)
Missing 1 1 1 5 3 4
aTwo or more conditions of MI, stroke or diabetes
b KYH values calibrated to account for differences in laboratory measurements between studies
c Mean values standardized for age and sex to 2013 European standard population
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The prevalence of LDL-C ≥ 4.0mmol/L was higher in KYH
than Tromsø 7 for all three conditions with the largest mag-
nitude of effect in those with MI or stroke (Table 3).
Proportion meeting treatment targets for blood pres-
sure in each study is shown in Table 4. Despite higher
use of antihypertensive medication in KYH, more partic-
ipants met the treatment guidelines in Tromsø 7 for all
conditions. For MI and stroke, the odds ratios (compar-
ing Tromsø 7 and KYH) were similar (2–3 times higher)
whether considering all participants or when restricted
to those on medication. Among those with diabetes, the
odd ratios were smaller and confidence intervals crossed
1 when restricting analyses to those on medication. The
prevalence of SBP ≥160 mmHg or DBP ≥100 mmHg was
higher in KYH than Tromsø 7 for all conditions.
Adjustment for education and visiting a doctor did not
explain the between study differences.
Sensitivity analyses with more specific case definition
Sensitivity analyses showed that more specific case defi-
nitions of diabetes for KYH and Tromsø 7 (Supplemen-
tary Table 1) and MI for KYH (Supplementary Table 2)
made no material difference.
Discussion
In this paper we have compared the pharmacological man-
agement of modifiable CVD risk factors between participants
reporting MI, stroke, and diabetes in two population-based
studies conducted in Russia and Norway.
The use of lipid-lowering medications was higher in
Tromsø 7, with a particularly large difference among
those with a history of MI. Reduction of LDL-C to the
guidelines was very low in both countries (age and sex
standardized prevalence of control: MI 5.1% vs 10.1%
stroke 11.6% vs 5.8% diabetes 24.9% vs 23.3%). Con-
versely the use of antihypertensive medications was
lower in Tromsø 7. Despite this, the proportion meeting
treatment targets for blood pressure was lower in KYH
than Tromsø 7 for all conditions (age and sex standard-
ized prevalence of control: MI 51.8% vs 76.3% stroke
49.5% vs 69.6% diabetes 72.2% vs 45.5%).
It is important that the very high levels of use of anti-
hypertensive medications in KYH were not reflected in
lower blood pressures. Further investigation is need to
explain this but it may reflect, in part, differences in how
people obtain medication in Russia compared to
Norway. In Russia antihypertensive and lipid-lowering
medications can be obtained from pharmacies without a
prescription so high levels of medication use do not ne-
cessarily reflect equivalent levels of monitoring by a
health professional. Also, medication use was assessed
by participants’ reports of what medications they were
using and we have not assessed adherence to medica-
tion. Intermittent use of medication (for example only
Fig. 1 Age- and sex-standardised prevalence of the use of lipid-lowering medications in KYH and Tromsø 7 in participants reporting MI, stroke or diabetes
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when feeling unwell) could be a factor in poor levels of
control. There may be other reasons for poor blood
pressure control in Russia, such as a co-morbid chronic
kidney disease, which need to be investigated.
Here we have investigated pharmacological management
in a general population setting reflecting what actually hap-
pens in practice. Our findings can be contrasted with EURO-
ASPIRE IV [4] which took place in a controlled clinical
setting. EUROASPIRE IV participants were hospital patients
where the quality of care may plausibly be higher than in the
general population. Compared to EUROASPIRE IV the age-
and sex-standardised prevalence of use of antihypertensive
medications (78.1%) was similar in the MI participants using
the broader definition of medication use in both Tromsø
7(73.3%) and KYH (78.7%). With this definition use of lipid-
lowering medications was also similar in EUROASPIRE IV
(86.6%) to Tromsø 7 (88.0%) while in KYH even with the
broad definition of medication use this was only 39.8%. This
is lower than the Russian EUROASPIRE IV centres where
74.6% of participants were taking statins [6]. This discrepancy
could be an indicator of regional variation in secondary pre-
vention of CVD within Russia. The EUROASPIRE centres
were all within the Moscow oblast and included specialized
clinical centres where adherence to treatment guidelines may
be higher than found throughout the whole country. In a
population survey in 13 regions of the Russian Federation
(2012–2013) only 40.0% of males and 28.1% of females with
history of MI were taking statins (for stroke patients these
numbers were 13.9 and 15.7%, for diabetes 12.2 and 12.7%)
[9]. However our finding that the target of LDL-C < 1.8
mmol/L was not met in the majority of participants even in
the Norwegian MI group is consistent with EUROASPIRE
IV (80.5% ≥1.8mmol/L) reflecting both the difficulty in
achieving this target and a general need for more intensive
lipid management in high risk groups throughout Europe.
This study has some limitations: firstly the number of par-
ticipants in each disease group was small. This was reduced
further when restricting to those taking medication. Despite
low power, there was strong evidence of large between study
differences in medication use and proportion meeting treat-
ment guidelines that are unlikely to be explained by chance.
Secondly, definitions of disease status and medication use
were self-reported and subject to potential misclassification,
with some differences in methodology in the two studies. Lit-
erature on reporting of self-reported medication use com-
pared to electronic registry data suggests high validity for
CVD medications [14–16]. Here we examined the impact of
different definitions of medication use and found the sub-
stantive findings remained the same. Literature on the valid-
ity of self-reported CVD morbidities, including validation of
self-reported stroke in a previous wave of the Tromsø Study
[17] suggests that these are specific but not sensitive, with
Fig. 2 Age- and sex-standardised prevalence of the use of antihypertensive medications in KYH and Tromsø 7 in participants reporting MI, stroke
or diabetes
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lower sensitivity for stroke and diabetes than MI [17–21].
While lower sensitivity of self-report means we may have
missed some participants eligible for inclusion this is
unlikely to have affected the results unless the people
excluded differed substantially in terms of medication use
and control from those included in the two studies and
under-reporting of disease status differed by study. The
sensitivity analyses with more specific case definitions
found the results were robust, although it should be noted
that they had even lower power than the main study due
to the smaller sample size when restricting to those identi-
fied with a stricter case definition.
Here we did not have the capacity within the data to deter-
mine stroke sub-types. There is debate about the use of sta-
tins following haemorrhagic stroke [22, 23], therefore
different proportions of stroke sub-type within the studies
could have impacted on subsequent medical management
with lipid-lowering medication. However the consistent find-
ing of differences across all three conditions suggests we have
identified a fundamental difference in pharmacological man-
agement. Similarly we did not have data on contraindications
for medication use (statin intolerance, hyperkalemia), how-
ever unless there are large differences in the populations in
prevalence of contraindications this is very unlikely to have
affected the study results.
Finally, participants were recruited from two cities in
Russia and one in Norway so the findings cannot be
considered representative of the whole of each country.
Conclusions
In conclusion we have found that among people with a self-
reported history of MI there was a lower level of use of lipid-
lowering medications in the Russian compared to Norwegian
study. In contrast we found higher levels of use of antihyper-
tensive medications in the Russian study but also that less
participants met treatment targets for blood pressure. Treat-
ment to target for total cholesterol was poor in both Russian
and Norwegian studies. Further work should investigate what
factors are responsible for this seeming paradox and how
management of modifiable risk factors for secondary preven-
tion could be improved.
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